The drug that changed treatment for the most common form of dwarfism has passed its pivotal test in a second, milder condition, and the detailed results were published Tuesday in NEJM Evidence alongside a presentation at the European Society for Paediatric Endocrinology meeting.
BioMarin announced that Voxzogo, its C-type natriuretic peptide analog approved for achondroplasia since 2021, produced positive Phase III results in hypochondroplasia, a related genetic condition that limits bone growth. The trial, CANOPY-HCH-3, is the first pivotal study of any drug in hypochondroplasia, which has no approved medicine from the FDA or the EMA. If regulators agree with the data, Voxzogo would become the first targeted therapy for the condition, with a potential 2027 launch.
The numbers, stated plainly
The study enrolled 80 children aged 3 to 17 with hypochondroplasia and height at least two standard deviations below average. They were randomized one to one to once-daily subcutaneous Voxzogo or placebo for 52 weeks.
The primary endpoint was annualized growth velocity, and the difference was unambiguous: a least squares mean advantage of 2.33 centimeters per year for the treated group, which grew 1.95 centimeters per year on average while the placebo group's growth velocity declined by 0.39 centimeters per year. Standing height showed a 2.35 centimeter difference, and height Z-score, the standardized measure that matters for long-term growth trajectory, improved by 0.39 standard deviations. Arm span difference was 1.03 centimeters. All three cleared statistical significance.
Two measures did not. The upper-to-lower body segment ratio, which captures whether growth is proportionate, and caregiver-reported quality-of-life scores did not reach significance under the study's hierarchical testing plan, though the point estimates favored the drug. The distinction matters for what regulators and families can expect: the drug makes children grow faster and taller, while the evidence on proportionality and on how families experience the difference is suggestive rather than proven.
Safety tracked the drug's established achondroplasia profile: most adverse events were mild, with no grade 3 or higher events, no treatment-related serious adverse events, no discontinuations, and no deaths. The single serious adverse event in the trial, a seizure, occurred in the placebo group.
The expansion logic
Voxzogo works downstream of the FGFR3 receptor that causes both conditions. In achondroplasia and hypochondroplasia, a faulty FGFR3 signal suppresses bone growth; the drug's C-type natriuretic peptide analog counteracts that suppression and lets endochondral bone growth proceed. The biology translates across the two conditions, which is why the hypochondroplasia trial was designed as an expansion rather than a new bet.
The commercial logic is equally clear. Voxzogo generated $927 million in full-year 2025 sales, up 26 percent, and has treated more than 5,000 children in over 50 countries. BioMarin estimates roughly 14,000 children with hypochondroplasia in its global footprint may be eligible. A supplemental application for the new indication is already with the FDA, with an EMA submission on track. A separate supplemental application seeking full approval in achondroplasia has a decision date of February 28, 2027.
The achondroplasia market is also shifting under the expansion. Competitors are advancing through development, and a second approved indication, especially one with no approved alternatives at all, gives Voxzogo a moat that its original indication no longer provides alone.
What the result does and does not mean
For families, the honest summary follows the data's own boundaries. The trial shows treated children grew faster and taller over a year, with a clean safety profile, in a condition where no medicine exists. It does not yet show whether the growth advantage persists into adolescence and adulthood, whether it changes how children and caregivers experience the condition day to day, or whether regulators will accept the package. The open-label extensions that follow every successful pivotal study in this field will answer the durability question over time.
For the field, the result extends a principle that achondroplasia established: growth conditions caused by single genetic errors are treatable with mechanism-based drugs. Hypochondroplasia was long considered too mild to justify a pivotal program. The CANOPY-HCH-3 result suggests the bar for what is treatable keeps moving, and that the mildness of a condition no longer decides whether it gets a medicine.
Primary sources
- BioMarin press release on the CANOPY-HCH-3 detailed results.
- NEJM Evidence publication of the Phase III hypochondroplasia results.
- Contemporary Pediatrics and Fierce Pharma for the endpoint detail and market context.